Elizabeth Levy

Dr. Elizabeth Levy


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PKPonien kou
Ponien kou
ELElizabeth Levy
Elizabeth Levy
ANAn Duc Nguyen
An Duc Nguyen
DZDonglu Zhang
Donglu Zhang
SCShu Chen
Shu Chen
VSvijay sethuraman
vijay sethuraman
Proteolysis-Targeting Chimeras (PROTACs) are a promising new technology in drug development. They have rapidly evolved in recent years, with several of them in clinical trials. While most of these advances have been associated with monovalent protein degraders, bivalent PROTACs have also entered clinical trials, although progression to market has been limited. One of the reasons is the complex physicochemical properties of the heterobifunctional PROTACs. A promising strategy to improve pharmacokinetics of highly lipophilic compounds, such as PROTACs, is encapsulation in liposome systems. Here we describe liposome systems for intravenous administration to enhance the PK properties of two bivalent PROTAC molecules, by reducing clearance and increasing systemic coverage. We developed and characterized a PROTAC-in-cyclodextrin liposome system where the drug was retained in the liposome core. In PK studies at 1 mg/kg for GNE-01 the PROTAC-in-cyclodextrin liposome, compared to the solution formulation, showed a 80- and a 380-fold enhancement in AUC for mouse and rat studies, respectively. We further investigated the same PROTAC-in-cyclodextrin liposome system with the second PROTAC (GNE-02), where we monitored both lipid and drug concentrations in vivo. Similarly, in a mouse PK study of GEN-02, the PROTAC-in-cyclodextrin liposome system exhibited enhancement in plasma concentration of a 23× increase over the conventional solution formulation. Importantly, the lipid CL correlated with the drug CL. Additionally, we investigated a conventional liposome approach for GNE-02, where the PROTAC resides in the lipid bilayer. Here, a 5× increase in AUC was observed, compared to the conventional solution formulation, and the drug CL was faster than the lipid CL. These results indicate that the different liposome systems can be tailored to translate across multiple PROTAC systems to modulate and improve plasma concentrations. Optimization of the liposomes could further improve tumor concentration and improve the overall therapeutic index (TI). This delivery technology may be well suited to bring novel protein targeted PROTACs into clinics.

26 August 2026 in ACS Omega
Verified
Journal Article
Open access
ELElizabeth Levy
Elizabeth Levy
KSKaren E. Samy
Karen E. Samy
AAAndrea Anelli
Andrea Anelli
DLDennis H. Leung
Dennis H. Leung
Early stage preclinical drug formulation development can be impacted by limited materials and time, especially when making rapid, data-driven decisions is critical. An important parameter to consider is dose linearity, as this can guide the selection between determining if a conventional or enabled formulation strategy is necessary to achieve the expected target exposure as the dose is escalated. This work explores the application of machine learning models to predict dose linearity for compounds administered to the mouse species based on the molecular properties. We utilize a diverse set of models, including Random Forest, XGBoost, LASSO, Neural Networks, and TabPFN, using two distinct data sets for training: a full data set including measured and calculated descriptors and a more accessible data set containing only the RDKit descriptors. Cross-validation was applied with random and scaffold splits, and model performance was evaluated based on a test data set containing 10% of the full data set that was held out during training. Our analysis indicated that the ML models trained with the full descriptors were comparable to the SMILES-only derived descriptors with RDKit. Additionally, while most models achieved comparable performance, LASSO was prioritized due to the interpretability, feature selection, and resistance to overfitting smaller data sets. With a random split and RDKit-only descriptors, the LASSO model resulted in 90.9% precision in the test set and 88.0% accuracy. Precision was optimized to minimize false positives, as incorrectly determining that a compound would not be less-than-dose proportional, where a conventional vehicle would be sufficient, has a higher cost than false negatives. To further evaluate the model’s capacity to apply to novel chemical compounds, a scaffold split was tested. A gap in performance was seen with a precision of 89.3% in training and 80.9% in testing, highlighting the challenges in predicting outcomes with new, chemically unique architectures. A significant finding of this work is the robust performance of the models trained solely on accessible RDKit descriptors, demonstrating that a tool can be developed without more resource-intensive measured data. Overall, this research focuses on a data-driven approach based on dose linearity prediction for whether a conventional, nonsolubilizing vehicle is sufficient or if an enabled formulation would be required to achieve the target exposures. The application to forecast a compound’s dose linearity risk with only the chemical structures provides a valuable tool to guide early formulation strategy and accelerate compound evaluation and preclinical development during the drug discovery phase.